tiprankstipranks
Advertisement
Advertisement
Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
PremiumThe FlyRhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord
1M ago
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials
Premium
Company Announcements
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials
1M ago
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on Rhythm as PWS Data Strengthens Thesis; $136 Price Target Maintained
1M ago
Rhythm Pharmaceuticals Signals Momentum Despite Rising Costs
PremiumCompany AnnouncementsRhythm Pharmaceuticals Signals Momentum Despite Rising Costs
2M ago
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
Premium
The Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
2M ago
Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)
Premium
TipRanks Newswire
Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)
2M ago
Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M
PremiumThe FlyRhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M
3M ago
Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
Premium
The Fly
Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
3M ago
RYTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
RYTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100